Ironwood Pharmaceuticals Inc. [IRWD] Insider John Minardo sells 7,045 Shares for $7,045

0
31

Ironwood Pharmaceuticals Inc.’s filing revealed that its Chief Legal Officer John Minardo unloaded Company’s shares for reported $70732.0 on Aug 14. In the deal valued at $10.04 per share,7,045 shares were sold. As a result of this transaction, John Minardo now holds 192,195 shares worth roughly $ 1.69 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.

Sponsored

Then, Silver Ronald sold 1,976 shares, generating $19,839 in total proceeds. Upon selling the shares at $10.04, the Principal Accounting Officer now owns 134,172 shares.

Before that, MCCOURT Thomas A sold 26,632 shares. Ironwood Pharmaceuticals Inc. shares valued at $284,962 were divested by the Chief Executive Officer at a price of $10.70 per share. As a result of the transaction, MCCOURT Thomas A now holds 758,284 shares, worth roughly $6.67 million.

CapitalOne initiated its Ironwood Pharmaceuticals Inc. [IRWD] rating to an Overweight in a research note published on Tuesday, September 02, 2022; the price target was $15. PT values the company’s stock at a premium of 41.4 to its Tuesday closing price.

Price Performance Review of IRWD

On Tuesday, Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] saw its stock fall -5.08% to $8.79. On the same session, the stock had its day’s lowest price of $8.775, but rose to a high of $9.27. Over the last five days, the stock has lost -3.51%. Ironwood Pharmaceuticals Inc. shares have fallen nearly -29.06% since the year began. Nevertheless, the stocks have fallen -18.84% over the past one year. While a 52-week high of $12.66 was reached on 01/06/23, a 52-week low of $8.75 was recorded on 08/31/23. SMA at 50 days reached $10.19, while 200 days put it at $10.94. A total of 2.26 million shares were traded, compared to the trading of 2.6 million shares in the previous session.

Levels Of Support And Resistance For IRWD Stock

The 24-hour chart illustrates a support level at 8.62, which if violated will result in even more drops to 8.45. On the upside, there is a resistance level at 9.12. A further resistance level may holdings at 9.44. The Relative Strength Index (RSI) on the 14-day chart is 36.28, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.75%. Stochastics %K at 26.84% indicates the stock is a holding.

How much short interest is there in Ironwood Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Ironwood Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -1.33 million shares to a total of 14.92 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 16.25 million shares. There was a decline of -8.91%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 15.60% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.74.

Ironwood Pharmaceuticals Inc. [IRWD] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 22,486,732 shares, or roughly 14.48% of the outstanding IRWD shares. In other words, the investor’s shares have risen by 273,265 from its previous 13-F filing of 22213467.0. Over the last quarter, SSgA Funds Management, Inc. purchased 546,647 shares of Ironwood Pharmaceuticals Inc., while LSV Asset Management bought 92,600 shares. At present, Dimensional Fund Advisors LP is holding 5,611,068 shares valued at $62.23 million. Renaissance Technologies LLC owned 5,319,453 shares of the company at the time of its most recent 13F filing, worth $58.99 million.

According to FactSet, Ironwood Pharmaceuticals Inc.’s share price will average $14.67 in the next year, based on opinions of analysts polled by the firm. This is up nearly 61.99 percent from its previous closing price of $9.26. Analysts expect Ironwood Pharmaceuticals Inc. stock to reach the higher price of $20.00, while the lowest price estimate is $9.00. However, 3 analysts have rated IRWD stock as an Overweight in their predictions for 2023.

LEAVE A REPLY

Please enter your comment!
Please enter your name here